Lakefront Biotherapeutics (LKFT) Stock Forecast & Price Target

Lakefront Biotherapeutics is viewed positively because gamgertamig appears to be a differentiated BCMA/CD3 bispecific with rapid, deep B-cell depletion, durable remissions, and a safety profile that may compare favorably with CAR-T, especially given the recent CAR-T setbacks cited. The company’s outsourced development partnership with GILD limits risk, while a strong balance sheet and favorable tax structure provide financial flexibility and a valuation floor for further in-licensing across therapeutic areas. Management expects dose-optimization data in 2H26 and registrational studies in 2027, and if autoimmune cytopenia and broader autoimmune indications support the current thesis, the asset could drive meaningful royalty revenue, potentially up to $885M annually from a roughly $4B WW opportunity.

Lakefront Biotherapeutics is viewed negatively because its value depends heavily on a small, early-stage pipeline and on successfully adding competitive assets at attractive valuations, yet those assets may never materialize. Limited quantitative data for gamgertamig, uncertainty over optimal dosing to balance CRS risk against cell depletion, and several BCMAxCD3 bispecific competitors in autoimmune disease all raise execution risk and could compress future commercial opportunity. As a non-revenue-generating company with unpredictable future revenues and expenses, it remains exposed to substantial stock volatility, and if '3667 disappoints or is not out-licensed, shares could trade lower.